Organizational structure
The institute’s highest governing body is the Supervisory Board (SB), in which all TI Pharma partners and participants are represented. Once a year the SB approves the overall research program, the operational plan, and the institute’s budget.
Executive Board
The Executive Board (EB), which is appointed by the SB, consists of seven members drawn from the various “blood groups” that make up TI Pharma. Two members represent global pharmaceutical companies. Two members represent small and medium sized enterprises. Three members represent clinical and preclinical academic researchers. The role of the board is to evaluate and monitor funding over individual projects, and acts as a sounding board for the Management Team.
Management Team
The Management Team (MT) is responsible for the day-to-day management of the Institute, monitors the progress and (scientific) quality of projects, acquires new partners and funding, and prepares the meetings of the EB and SB.
The MT is formed by a Managing Director and a Scientific Director. The Managing Director, Willem N. G. M. de Laat, Ph.D., is responsible for overall running TI Pharma. The Scientific Director, Professor Daan Crommelin, Ph.D., is responsible for monitoring the scientific quality of TI Pharma’s projects within the Strategic Research Program.
ISRC
An independent committee, the International Scientific Review Committee (ISRC), serves as advisor to the EB and the MT.
The ISRC is responsible for a (bi-) annual review of the institute, including visits to the participating groups. It assesses the balance in the overall project portfolio and overall quality, and performs an independent check on how TI Pharma is meeting its strategic objectives. The ISRC is composed of internationally reputed experts from industry and the universities, and a representative from the WHO to monitor the adherence to the Priority Medicines project.